| Identification | Back Directory | [Name]
RGX-104 free Acid | [CAS]
610318-54-2 | [Synonyms]
SB742881
RGX-104 free Acid
RGX-104 (free form)
610318-54-2 (FREE FORM) 610318-03-1 (HCL)
Benzeneacetic acid, 3-[(3R)-3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]butoxy]- | [Molecular Formula]
C34H33ClF3NO3 | [MDL Number]
MFCD31726291 | [MOL File]
610318-54-2.mol | [Molecular Weight]
596.08 |
| Chemical Properties | Back Directory | [Boiling point ]
677.1±55.0 °C(Predicted) | [density ]
1.246±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO:100.0(Max Conc. mg/mL);167.76(Max Conc. mM) | [form ]
Solid | [pka]
4.19±0.10(Predicted) | [color ]
White to off-white | [InChIKey]
ZLJZDYOBXVOTSA-XMMPIXPASA-N | [SMILES]
C1(CC(O)=O)=CC=CC(OCC[C@H](N(CC2=CC=CC(C(F)(F)F)=C2Cl)CC(C2=CC=CC=C2)C2=CC=CC=C2)C)=C1 |
| Hazard Information | Back Directory | [Uses]
RGX-104 is combination of a liver X receptor β agonist and GITR modulator for treatment of cancer.Liver X receptor beta agonist. | [in vivo]
Oral administration of RGX-104 (100 mg/kg, daily) to animals bearing palpable tumors significantly suppresses the growth of multiple cancer types. Co-administration of RGX-104 with anti-PD-1 is superior to administration of either RGX-104 or anti-PD-1 alone. Importantly, co-administration of RGX-104 with anti-PD-1 therapy is well tolerated by mice, with no overt signs of toxicity[1]. | Animal Model: | NOD SCID or RAG mice injected with 1×106 SKOV3 ovarian cancer cells[1]. | | Dosage: | 100 mg/kg. | | Administration: | Oral administration daily for about 60 days. | | Result: | Robustly suppressed tumor growth and progression. |
|
|
| Company Name: |
InvivoChem Gold
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|